Author: Ju, Jingyue; Kumar, Shiv; Li, Xiaoxu; Jockusch, Steffen; Russo, James J.
Title: Nucleotide Analogues as Inhibitors of Viral Polymerases Cord-id: dpcpg5c1 Document date: 2020_1_31
ID: dpcpg5c1
Snippet: Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad s
Document: Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.
Search related documents:
Co phrase search for related documents- active site and low fidelity: 1, 2, 3, 4, 5
- active triphosphate form and additional information: 1
- active triphosphate form and low fidelity: 1, 2
- active triphosphate form rdrp inhibit and additional information: 1
Co phrase search for related documents, hyperlinks ordered by date